Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes

被引:533
作者
Rozema, David B.
Lewis, David L.
Wakefield, Darren H.
Wong, So C.
Klein, Jason J.
Roesch, Paula L.
Bertin, Stephanie L.
Reppen, Tom W.
Chu, Qili
Blokhin, Andrei V.
Hagstrom, James E.
Wolff, Jon A.
机构
[1] Mirus Bio Corp, Madison, WI 53719 USA
[2] Univ Wisconsin, Waisman Ctr, Dept Pediat, Madison, WI 53719 USA
[3] Univ Wisconsin, Waisman Ctr, Dept Med Genet, Madison, WI 53719 USA
关键词
pH labile bonds; nonviral siRNA delivery; siRNA-polymer conjugates; endosomolytic polymers;
D O I
10.1073/pnas.0703778104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Achieving efficient in vivo delivery of siRNA to the appropriate target cell would be a major advance in the use of RNAi in gene function studies and as a therapeutic modality. Hepatocytes, the key parenchymal cells of the liver, are a particularly attractive target cell type for siRNA delivery given their central role in several infectious and metabolic disorders. We have developed a vehicle for the delivery of siRNA to hepatocytes both in vitro and in vivo, which we have named siRNA Dynamic PolyConjugates. Key features of the Dynamic PolyConjugate technology include a membrane-active polymer, the ability to reversibly mask the activity of this polymer until it reaches the acidic environment of endosomes, and the ability to target this modified polymer and its siRNA cargo specifically to hepatocytes in vivo after simple, low-pressure i.v. injection. Using this delivery technology, we demonstrate effective knockdown of two endogenous genes in mouse liver: apolipoprotein B (apoB) and peroxisome proliferator-activated receptor alpha (ppara). Knockdown of apoB resulted in clear phenotypic changes that included a significant reduction in serum cholesterol and increased fat accumulation in the liver, consistent with the known functions of apoB. Knockdown of ppara also resulted in a phenotype consistent with its known function, although with less penetrance than observed in apoB knockdown mice. Analyses of serum liver enzyme and cytokine levels in treated mice indicated that the siRNA Dynamic PolyConjugate was nontoxic and well tolerated.
引用
收藏
页码:12982 / 12987
页数:6
相关论文
共 52 条
[1]  
Arias I. M., 1994, LIVER BIOL PATHOBIOL
[2]   Design and creation of new nanomaterials for therapeutic RNAi [J].
Baigude, Huricha ;
McCarroll, Joshua ;
Yang, Chao-shun ;
Swain, Pamela M. ;
Rana, Tariq M. .
ACS CHEMICAL BIOLOGY, 2007, 2 (04) :237-241
[3]   Progress towards in vivo use of siRNAs [J].
Behlke, MA .
MOLECULAR THERAPY, 2006, 13 (04) :644-670
[4]   Respective roles of TNF-α and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice [J].
Benihoud, K. ;
Esselin, S. ;
Descamps, D. ;
Jullienne, B. ;
Salone, B. ;
Bobe, P. ;
Bonardelle, D. ;
Connault, E. ;
Opolon, P. ;
Saggio, I. ;
Perricaudet, M. .
GENE THERAPY, 2007, 14 (06) :533-544
[5]   LIGAND SIZE IS A MAJOR DETERMINANT OF HIGH-AFFINITY BINDING OF FUCOSE-EXPOSING AND GALACTOSE-EXPOSING (LIPO)PROTEINS BY THE HEPATIC FUCOSE RECEPTOR [J].
BIESSEN, EAL ;
BAKKEREN, HF ;
BEUTING, DM ;
KUIPER, J ;
VANBERKEL, TJC .
BIOCHEMICAL JOURNAL, 1994, 299 :291-296
[6]   Inhibition of respiratory viruses by nasally administered siRNA [J].
Bitko, V ;
Musiyenko, A ;
Shulyayeva, O ;
Barik, S .
NATURE MEDICINE, 2005, 11 (01) :50-55
[7]   Apolipoprotein B metabolism: Tracer kinetics, models, and metabolic studies [J].
Burnett, JR ;
Barrett, PHR .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2002, 39 (02) :89-137
[8]   A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides [J].
Chen, ZJ ;
Fitzgerald, RL ;
Averna, MR ;
Schonfeld, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (42) :32807-32815
[9]   Two categories of mammalian galactose-binding receptors distinguished by glycan array profiling [J].
Coombs, Peter J. ;
Taylor, Maureen E. ;
Drickamer, Kurt .
GLYCOBIOLOGY, 2006, 16 (08) :1C-7C
[10]   An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis [J].
Crooke, RM ;
Graham, MJ ;
Lemonidis, KM ;
Whipple, CP ;
Koo, S ;
Perera, RJ .
JOURNAL OF LIPID RESEARCH, 2005, 46 (05) :872-884